A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma | MicrobiomeTrials
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2024-09-16Est. Completion: 2032-05-18
Enrollment target: 116 participants
Locations
Johns Hopkins Hospital, Baltimore, Maryland, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
University of Michigan Health, Ann Arbor, Michigan, United States
NYU Langone Health Perlmutter Cancer Center, New York, New York, United States
Stony Brook University Hospital, Stony Brook, New York, United States
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
University of Washington, Seattle, Washington, United States